Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration accepted its new drug application for bepirovirsen, an antisense oligonucleotide targeting hepatitis B surface antigen, for priority review and granted the drug Breakthrough Therapy designation. The acceptance came on April 28, 2026, with a PDUFA target action date of October 26, 2026.
Bepirovirsen is supported by Phase 3 B‑Well 1 and B‑Well 2 trials, which have shown promising functional cure rates. Functional cure is defined as sustained loss of hepatitis B surface antigen with undetectable viral DNA for at least 12 months after stopping therapy.
Chronic hepatitis B affects more than 250 million people worldwide and 1.7 million in the United States. Current standard of care requires lifelong nucleos(t)ide analog therapy and achieves functional cure in only about 1 % of patients. Bepirovirsen could change that landscape by offering a first‑in‑class treatment that may achieve higher cure rates.
The breakthrough designation reflects preliminary clinical evidence that bepirovirsen may provide substantial improvement over existing therapies. The priority review designation shortens the FDA’s action window from the usual 10 months to 6 months, accelerating the potential market launch.
Ionis’s strategy has shifted from a discovery‑focused model to a fully integrated commercial‑stage biotechnology company. The accelerated review is a key commercial milestone that could bring earlier revenue streams and strengthen the company’s antisense portfolio. Ionis’s market capitalization is $11.93 billion, and the company reported $943.71 million in revenue for the last twelve months with a gross profit margin of 1.29 %. Analysts do not expect profitability in 2026, but the licensing agreement with GSK, signed in 2019, provides upfront payments, milestone payments, and tiered royalties that help offset development costs.
CEO Brett P. Monia said, “Over one million people in the U.S. are living with chronic hepatitis B and as of today, require lifelong antiviral therapy to suppress the virus. As the first medicine to deliver clinically meaningful functional cure rates, bepirovirsen is uniquely positioned to effectively treat CHB based on its potential to reduce the replication of hepatitis B virus, suppress hepatitis B surface antigen and stimulate the immune system. This milestone reflects the broad impact of Ionis’ science, and we look forward to the potential for bepirovirsen to help millions of people living with this devastating condition around the world.”
The FDA acceptance follows Ionis’s earlier Fast Track designation in February 2024 and the company’s ongoing collaboration with GSK, which has provided significant financial support and a global commercialization pathway. Ionis’s balance sheet remains strong, with liquid assets exceeding short‑term obligations and a current ratio of 3.83, giving the company flexibility to fund continued development and potential commercialization of bepirovirsen.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.